Loading company…
Cambridge-based Praxis Precision Medicines researches and develops therapies for neurological disorders such as epilepsy and essential tremor.
Praxis Precision Medicines, Inc. was founded in 2015 by David Goldstein, Kiran Reddy and Steven Petrou, and is based in Massachusetts, US. It uses genome sequencing to find brain regions involved in diseases such as epilepsy, mood disorders, pain syndromes and movement disorders. Its pipeline includes PRAX-944 for essential tremor and PRAX-628 for specific types of epilepsy. In March 2024 it raised USD 187.5 million in a private placement, selling 3.31 million shares at USD 56.5 each on the Nasdaq Global Select Market.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in